In a decisive move that underscores a strategic pivot, IMC RARE EARTHS LTD, formerly known as IM Cannabis Corp., has completed a significant transaction that marks a new chapter in its corporate trajectory. On September 29, 2026, the company finalized the sale of IMC Holdings to Slil.com Holding Ltd., a transaction that not only redefines its operational focus but also promises to fortify its financial standing.
The sale involved the transfer of all shares of IMC Holdings, along with its European-focused operations, to Slil.com Holding Ltd. This strategic divestiture allows IMC RARE EARTHS LTD to concentrate its resources and efforts on its Israeli medical-cannabis operations, which were retained under IMC Holdings. This reorganization is a calculated move to streamline operations and enhance the company’s core competencies in the Israeli market.
Financially, the transaction is poised to bolster the company’s balance sheet significantly. By shedding the European operations, IMC RARE EARTHS LTD is expected to see an improvement in shareholders’ equity and working capital. Moreover, the reduction in consolidated liabilities associated with the sold assets is anticipated to provide a more robust financial foundation, enabling the company to pursue further growth opportunities with greater agility.
Notably, the transaction was executed without the issuance of new securities, a decision that underscores the company’s commitment to maintaining financial discipline and shareholder value. This approach not only preserves the existing capital structure but also reflects a strategic focus on leveraging internal resources for future growth.
The transaction, which involved a related-party element, was approved by a special committee of independent directors, ensuring that the interests of all stakeholders were duly considered. The CEO of IM Cannabis, who also owns the buyer, Slil.com Holding Ltd., was involved in the deal, highlighting the intricate relationships within the corporate landscape.
As IMC RARE EARTHS LTD transitions to its new operational focus, the company is poised to capitalize on the burgeoning opportunities within the Israeli medical-cannabis sector. This strategic realignment is expected to enhance the company’s competitive edge and drive sustainable growth in the long term.
In conclusion, the sale of IMC Holdings represents a pivotal moment for IMC RARE EARTHS LTD, marking a shift towards a more focused and financially robust operational model. As the company continues to assess further opportunities, stakeholders can anticipate a future characterized by strategic growth and enhanced shareholder value.
